Menu

Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


23. October 2019 | 07:54 CET

AURORA, BEVCANNA, EXMCEUTICALS - CANADA GETTING READY FOR CANNABIS 2.0

  • Cannabis

The consulting firm Deloitte has taken a close look at the cannabis industry and evaluated food and extracted products for the cannabis 2.0 market. In their analysis, the experts came to the conclusion that the annual Canadian market for food and alternative cannabis products is worth CAD 2.7 billion. The vast majority of this emerging cannabis 2.0 market will be products based on cannabis extracts, including foods, which the analysis puts at CAD 1.6 billion alone. But there are other significant opportunities, including cannabis-infused beverages with CAD 529 million, health products with CAD 174 million, concentrates with CAD 140 million, tinctures with CAD 116 million and capsules with CAD 114 million.

time to read: 1 minutes by Mario Hose


Jonathan Summers, CEO, EXMceuticals Inc.
"[...] In being able to grow in some of the best natural conditions in the world along the equator, Africa offers enormous advantages for cannabis cultivation. [...]" Jonathan Summers, CEO, EXMceuticals Inc.

Full interview

 

LEGALIZATION PROVIDES FOUNDATION FOR NEW MARKETS

The realisation of this considerable market potential will take some time, according to the Deloitte experts, because many cannabis products in these categories will only be available in sufficient quantities over time. Deloitte's industry representatives see cannabis 2.0 as a catalyst for the Canadian market, which is divided into two different target groups, in the context of further legalisation in October 2019.

Firstly, experienced cannabis users, such as millennials and younger people, already consume cannabis several times a week and are open to new products.

NEW CONSUMER GROUPS OFFER POTENTIAL

As the second target group of a new cannabis boom, the Deloitte experts see the beginners and the curious. Usually they are not interested in flammable cannabis. This new conservative type of user, typically middle-aged and university educated, focuses on family needs or other responsibilities and consumes cannabis less than once a month.

These consumers are expected to be attracted to more familiar formats, particularly foods such as baked goods, confectionery and teas. The low doses available in food and micro-doses are ideal for these consumers and provide a more convenient starting point for their cannabis experience.

NEW COMPANIES OFFER FAVOURABLE VALUATIONS

The outlined development of the cannabis 2.0 market becomes interesting in connection with the increasing legalization of cannabis products around the globe and against this background not only the first series like Aurora and Canopy Growth are exciting, but also the innovative new players with interesting business models or cost-efficient structures. In recent years, the young companies have been able to learn from the weaknesses and strengths of the already established billion-euro companies.

BevCanna Enterprises Inc., a developer and manufacturer of cannabinoid-based beverages and consumer goods for private labels and white label customers, is just as interesting as EXMceuticals Inc., a company that produces CBD of the highest quality in various African countries and wants to offer it in large quantities worldwide. The two companies are currently valued at less than CAD 50 million on the stock exchange. Jonathan Summers, Chairman of EXMceuticals, will present the company this year at the German Equity Forum in Frankfurt. If Deloitte's market assessment proves to be true and this trend continues globally, then these two companies will certainly be attractively valued from today's perspective. We will see.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

15. July 2020 | 12:23 CET

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

  • Cannabis

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

Read

19. May 2020 | 15:02 CET

Aphria, Aurora Cannabis, Canopy Growth, EXMceuticals - do not miss the entry!

  • Cannabis

The nationwide and anonymous advertising format of Deutsche Post is called POSTAKTUELL and is published regularly in large print runs. The stack of advertising is wrapped in a foil and the practical added value for the recipient is the TV guide. The front of POSTAKTUELL is particularly eye-catching and anyone who advertises there will reach a lot of people. In the meantime, advertising for products and applications with active ingredients from the cannabis plant is already being done there. CBD reaches the general public and despite the Corona Pandemic, the industry's stocks are running in turnaround mode and have left the lows.

Read

23. March 2020 | 15:00 CET

Aurora Cannabis, Bayer, EXMceuticals - ready for the time after Corona

  • Cannabis

The cannabis hype was over and then came the corona crisis. Investors who believed in the active ingredient of cannabis and put money into the shares of companies in this industry are now likely to be sitting on a huge loss in most cases. It all started with the idea of a few companies to make one of the oldest medicinal plants in the world acceptable for general use within the framework of legalization. However, high margins and a large market soon led to competition and a brokerage industry was earning a lot of money - soon several hundred cannabis companies were listed on the stock exchange.

Read